购物车0
产品总数：60957
| 中文名称 |
Deferoxamine
|
|---|---|
| 中文别名 |
去铁胺;去铁敏;3-癸酮
|
| 英文名称 |
Deferoxamine
|
| 英文别名 |
N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide;desferrioxamine;Deferoxamine;N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobutanamido)pentyl)succinam...;Deferoxamin;Deferoxamine B;Deferoxaminum;Deferrioxamine;Deferrioxamine B;Desferal;Desferin;Desferrioxamine B;desferrioxamine mesylate;N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide;Deferoxamine B; Deferriferrioxamine B; Deferrioxamine;N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide;KBio2_004997;AB00053447;NCGC00178802-02;NSC527604;C25H48N6O8;UNII-J06Y7MXW4D;N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid;NSC268993;NCGC00178802-01;desferrioxamine-B;DTXSID7022887;Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-;D03670;N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid;Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-;DEFEROXAMINE [INN];3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-;Ba 29837 (Salt/Mix);deferoxamine-mesylate;SBI-0051332.P003;Desferoxamine b;AKOS016004824;HY-B1625;CHEBI:4356;Desferal (Salt/Mix);CS-0013559;BRD-K09821361-066-08-4;Desferex;SCHEMBL34571;Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-;Deferoxamide B;DF B;Ferrioxamine B, N-benzoyl-;C06940;BCP16524;Ba 33112;Prestwick2_000725;Desferriferrioxamin B;LS-124964;70-51-9;30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone;F11488;DEFEROXAMINE [HSDB];BDBM47715;KBio2_006508;EINECS 200-738-5;1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane;N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid;Cordaneurin;AB00053447_14;Q-200933;Spectrum4_000311;DFOM;HSDB 3311;BSPBio_000650;BRD-K09821361-066-15-9;CGH-749B;SMR000058548;Deferoxamina [INN-Spanish];Desferan;KBioGR_002429;J06Y7MXW4D;Dfo-b;DEFEROXAMINE [USAN];2C10H20N2O3.C5H13N.C3H7NO2;N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide;NSC-527604;N-[5-[[4-[5-[acetyl(hydroxy)amino]penty...
|
| Cas No. |
70-51-9
|
| 分子式 |
C25H48N6O8
|
| 分子量 |
560.68
|
| 包装储存 |
Powder -20°C 3 years；4°C 2 years
|
| 产品详情 |
Deferoxamine (Deferoxamine B) 是一种铁螯合剂 (结合 Fe(III) 和许多其他金属阳离子)，被广泛用于减少铁在组织中的积累和沉积。Deferoxamine 具有较好的抗氧化活性，可上调 HIF-1α 水平。Deferoxamine 还具有抗增殖活性，能诱导癌细胞凋亡和自噬。Deferoxamine 可用于糖尿病、神经退行性疾病以及抗癌和抗 COVID-19 的研究。
|
|---|---|
| 生物活性 |
Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
|
| 性状 |
Solid
|
| 体外研究(In Vitro) |
Deferoxamine (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells.Deferoxamine (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels.Deferoxamine (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.Deferoxamine (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs.Deferoxamine (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs.Deferoxamine (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 体内研究(In Vivo) |
Deferoxamine (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice.
Deferoxamine (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years；4°C 2 years
|
| ClinicalTrial |
|
| 参考文献 |
[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e. [2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47.
|
| 溶解度数据 |
In Vitro: DMSO : 12.5 mg/mL (22.29 mM; ultrasonic and warming and heat to 60°C)配制储备液
|
|---|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
